



THE  
BLADDER CANCER  
COMPANY

## Photocure ASA: Exercise of employee share options

Oslo, Norway, 6 December 2021: Reference is made to the stock exchange release by Photocure ASA ("**Photocure**" or the "**Company**") published on 3 December 2021 regarding exercise of share options.

The price for option shares sold by the primary insider, Susanne Strauss, VP and General Manager of Europe, has been determined at a price of NOK 94.2502 per share.

The primary insider having exercised options has used the net proceeds from the sale of option shares to purchase 1,392 shares in Photocure at a price per share of NOK 94.2502.

Primary insider notification pursuant to the market abuse regulation article 19 is attached.

For further information, please contact:

### **Photocure**

CFO Erik Dahl

Tel: +47 450 55 000

Email: [ed@photocure.com](mailto:ed@photocure.com)

### **About Photocure ASA**

Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at [www.photocure.com](http://www.photocure.com), [www.hexvix.com](http://www.hexvix.com) or [www.cysview.com](http://www.cysview.com)

All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to the market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading Act.